Eyeworld CME Supplements

EW_FEB 2016 Supported by unrestricted educational grants from Alcon Laboratories and Abbott Medical Optics

This is a supplement to EyeWorld Magazine that doctors can take a test after reading and receive CME credits for.

Issue link: http://cmesupplements.eyeworld.org/i/633030

Contents of this Issue

Navigation

Page 0 of 5

Supplement to EyeWorld Month Year Eric Donnenfeld, MD Dismantling barriers: Clinical pearls and practical guidance to implement laser-assisted cataract surgery Supported by unrestricted educational grants from Alcon Laboratories and Abbott Medical Optics Accreditation Statement This activity has been planned and imple- mented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Society of Cataract & Refractive Surgery (ASCRS) and EyeWorld. ASCRS is accredited by the ACCME to provide continuing medical education for physicians. Educational Objectives Ophthalmologists who participate in this activity will: • Analyze the quality and quantity of the most recently available studies on LACS • Describe accessibility pathways and reim- bursement and practice flow models • Develop a customized plan for appropriate patient education and staff support to facilitate integration into practice Designation Statement The American Society of Cataract & Refractive Surgery designates this enduring materials educational activity for a maximum of 1.0 AMA PRA Category 1 Credits. ™ Physicians should claim only credit commensurate with the extent of their participation in the activity. Claiming Credit To claim credit, participants must visit bit.ly/1NTTdSp to review content and down- load the post-activity test and credit claim. All participants must pass the post-activity test with a score of 75% or higher to earn credit. Alternatively, the post-test form included in this supplement may be faxed to the number indicated for credit to be awarded, and a certificate will be mailed within 2 weeks. When viewing online or downloading the material, standard Internet access is required. Adobe Acrobat Reader is needed to view the materials. CME credit is valid through August 31, 2016. CME credit will not be awarded after that date. Notice of Off-Label Use Presentations This activity may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. ADA/Special Accommodations ASCRS and EyeWorld fully comply with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Any participant in this educational program who requires special accommodations or services should contact Laura Johnson at ljohnson@ascrs.org or 703- 591-2220. Financial Interest Disclosures Eric Donnenfeld, MD, has received a retainer, ad hoc fees or other consulting income from: Abbott Medical Optics Inc., AcuFocus Inc., Alcon Laboratories Inc., Allergan, AqueSys Inc., Bausch + Lomb, CRST, Elenza, Glaukos Corporation, Icon Biosciences, Kala Phar- maceuticals, Katena, Mati Pharmaceuticals, Merck & Co. Inc., Mimetogen Pharmaceu- ticals USA Inc., NovaBay, OcuHub, Odyssey Medical Inc., Omeros Corporation, Pfizer Inc., PRN, RPS, Shire Pharmaceuticals, Strathspey Crown, TearLab, and TCL. Gary Foster, MD, has received a retainer, ad hoc fees or other consulting income from and has received research funding from: AcuFocus Inc., Alcon Laboratories Inc., and Ivantis Inc. He is a member of the speakers bureau of Alcon Laboratories Inc., and has received research funding from Bausch + Lomb. Dr. Foster has an investment interest in Strathspey Crown. Tal Raviv, MD, has received a retainer, ad hoc fees or other consulting income from Abbott Medical Optics, Alcon Laboratories Inc., and Glaukos Corporation. He has an investment interest in Yosicare Health. Robert Weinstock, MD, has received a retainer, ad hoc fees or other consulting income from: Abbott Medical Optics, Alcon Laboratories Inc., Bausch + Lomb, Drs Allergy Formula, i-Optics, LENSAR Inc., Leica, Omeros Corporation, STAAR Surgical, TrueVision, and WaveTec Vision. He has investment interests in: Drs Allergy Formula and TrueVision. Staff members: Laura Johnson and Erin Schallhorn have no ophthalmic-related financial interests. by Eric Donnenfeld, MD New perspectives on cataract surgery Dr. Donnenfeld practices with Ophthalmic Consultants of Long Island and Connecticut and is a clinical professor of ophthalmology, New York University, and trustee, Dartmouth Medical School. share recommendations for imple- menting LACS. They treat patients from different economic environ- ments throughout the country and are successful with LACS. This is a once-in-a-lifetime opportunity to improve patients' quality of vision. When questioned about barriers to adoption, more than 70% report- ed that LACS is not a viable econom- ic model for their practices. Our panel of experts will help surgeons dismantle the barriers that stand between them and LACS and B ased on results of the 2015 ASCRS Clinical Survey, which compiled feedback from more than 2,000 unique respondents, 68% of members do not have patients who receive laser-assisted cataract surgery (LACS) (Figure 1). The survey also revealed clinical areas where respondents thinks LACS may provide significant clini- cal benefits compared with conven- tional surgery: capsulorhexis, 59%; arcuate refractive incisions, 58%; and lens fragmentation, 45%. More than half of respondents were not very confident or not at all confident that there is an adequate reimbursement solution (private pay and/or insurance) to support LACS. This seems to be a limiting step for many surgeons. Figure 1. Sixty-eight percent of respondents currently do not have patients who receive femtosecond laser cataract surgery. Average Pct All 5% U.S. 6% Non U.S. 4% 50% 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% None, and have no plans to None, but plan to in the next 12 months 1–5% 6–10% 11–20% 21–40% 41–60% >60% What percentage of your cataract patients receive femtosecond laser cataract surgery? and practical guidance to implement Click to read and claim CME credit

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld CME Supplements - EW_FEB 2016 Supported by unrestricted educational grants from Alcon Laboratories and Abbott Medical Optics